EMERGENT BIOSOLUTIONS INC. lobbying for EMERGENT BIOSOLUTIONS INC

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 14, 2026

Expenses

$730,000.00

What this organization spent lobbying with its own staff. Reported using C: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Office of Natl Drug Control Policy (NDCP)
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 5252
HOPE Act

Lobbying activity 4

Homeland Security

- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Disaster Planning/Emergencies

- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Budget/Appropriations

- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Health Issues

- Reauthorization of Protecting Americans from All-Hazards Preparedness Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY27 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27 - Tribal Opioid Response Grant funding for FY27 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act